LABELS · 27102784-f56d-4edd-b68b-f8cc89f5b993

Levothyroxine Sodium

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-06-03
Captured: 2026-09-09T23:37:42.544548+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6), Drug Interactions (7.7) and Overdosage (10)]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning • Thyroid hormones, including levothyroxine sodium tablets should not be used for the treatment of obesity or for weight loss. • Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity (6, 10).

Indications and usage: exact source text

1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine sodium tablets is L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (1) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

Full extracted label fields

application numbers

NDA021342

boxed warning exact

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6), Drug Interactions (7.7) and Overdosage (10)]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning • Thyroid hormones, including levothyroxine sodium tablets should not be used for the treatment of obesity or for weight loss. • Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity (6, 10).

brand names

Levothyroxine Sodium

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56c633a9-3f64-46bd-b93f-afbff92b5559

generic names

LEVOTHYROXINE SODIUM

27102784-f56d-4edd-b68b-f8cc89f5b993

indications and usage exact

1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine sodium tablets is L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (1) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

indications and usage tables exact

is original packager

manufacturer names

Bryant Ranch Prepack

matched search terms

cancer

package ndcs

71335-9762-1
71335-9762-2
71335-9762-3
71335-9762-4
71335-9762-5
71335-9762-6
71335-9762-7
71335-9762-8

product ndcs

71335-9762

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

966221

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00100.json

meta

disclaimer

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

last updated

2026-09-09

license

https://open.fda.gov/license/

results

limit: 100
skip: 100
total: 830

terms

https://open.fda.gov/terms/

sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

url

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl effective time

20240603

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

substance names

LEVOTHYROXINE SODIUM

uniis

9J765S329G

verification flags

oncology_keyword_candidate_not_clinically_classified
spl_text_not_verified_identical_to_latest_approved_label
individual_indications_not_split_or_reconciled
not_identified_as_original_packager
fda_label_posted_after_spl_effective_date_requires_version_review

Drugs@FDA application source records

application number
NDA021342
payload
all indexed label documents
Appl No
021342
Application Docs Date
2002-03-01 00:00:00
Application Docs ID
15220
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21342lbl.pdf
Submission No
1
Submission Type
ORIG
Appl No
021342
Application Docs Date
2008-06-12 00:00:00
Application Docs ID
15221
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021342s008s014lbl.pdf
Submission No
8
Submission Type
SUPPL
Appl No
021342
Application Docs Date
2009-06-22 00:00:00
Application Docs ID
15222
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021342s016lbl.pdf
Submission No
16
Submission Type
SUPPL
Appl No
021342
Application Docs Date
2003-12-11 00:00:00
Application Docs ID
36692
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21342scs001_Levo-T_lbl.pdf
Submission No
1
Submission Type
SUPPL
Appl No
021342
Application Docs Date
2003-08-28 00:00:00
Application Docs ID
36693
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21342scs002_levoT_lbl.pdf
Submission No
2
Submission Type
SUPPL
Appl No
021342
Application Docs Date
2008-06-12 00:00:00
Application Docs ID
36694
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021342s008s014lbl.pdf
Submission No
14
Submission Type
SUPPL
Appl No
021342
Application Docs Date
2017-12-07 00:00:00
Application Docs ID
50625
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021342s023lbl.pdf
Submission No
23
Submission Type
SUPPL
Appl No
021342
Application Docs Date
2026-05-21 00:00:00
Application Docs ID
85838
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021342s028lbl.pdf
Submission No
28
Submission Type
SUPPL
all submission records
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
28
Submission Status
AP
Submission Status Date
2026-05-04 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
25
Submission Status
AP
Submission Status Date
2017-01-12 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
24
Submission Status
AP
Submission Status Date
2015-02-09 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
23
Submission Status
AP
Submission Status Date
2017-12-05 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
22
Submission Status
AP
Submission Status Date
2012-11-20 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
2
Submission No
20
Submission Status
AP
Submission Status Date
2011-03-09 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
16
Submission Status
AP
Submission Status Date
2009-06-14 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
14
Submission Status
AP
Submission Status Date
2008-06-10 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
8
Submission Status
AP
Submission Status Date
2008-06-10 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
2
Submission No
4
Submission Status
AP
Submission Status Date
2004-06-23 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
UNKNOWN
Submission Class Code ID
2
Submission No
3
Submission Status
AP
Submission Status Date
2004-06-23 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021342
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
2
Submission Status
AP
Submission Status Date
2003-08-21 00:00:00
Submission Type
SUPPL
Submissions Public Notes
application number
NDA021342
approval interpretation
Application linkage and approved submission are not indication-level current approval verification
current indication status
not_reconciled
drugsfda url
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021342
has approved submission record
true
latest approved submission date
2026-05-04
latest label selection rule
max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
latest posted label documents
Appl No
021342
Application Docs Date
2026-05-21 00:00:00
Application Docs ID
85838
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021342s028lbl.pdf
Submission No
28
Submission Type
SUPPL
official application record
Appl No
021342
Appl Public Notes
Appl Type
NDA
Sponsor Name
CEDIPROF INC
openfda application present
true
products
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
001
Reference Drug
0
Reference Standard
0
Strength
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
002
Reference Drug
0
Reference Standard
0
Strength
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
003
Reference Drug
0
Reference Standard
0
Strength
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
004
Reference Drug
0
Reference Standard
0
Strength
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
005
Reference Drug
0
Reference Standard
0
Strength
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
006
Reference Drug
0
Reference Standard
0
Strength
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
007
Reference Drug
0
Reference Standard
0
Strength
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
008
Reference Drug
0
Reference Standard
0
Strength
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
009
Reference Drug
0
Reference Standard
0
Strength
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
010
Reference Drug
0
Reference Standard
0
Strength
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
011
Reference Drug
0
Reference Standard
0
Strength
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021342
Drug Name
LEVO-T
Form
TABLET;ORAL
Product No
012
Reference Drug
0
Reference Standard
0
Strength
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA021342

brand names

Levothyroxine Sodium

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 419
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-depen
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 0

current approval status

not_reconciled

duplicate text group

dup-99df4090149782b179a0

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-ffd69331f9e18bb10735

label id

27102784-f56d-4edd-b68b-f8cc89f5b993

positive predicate support span

end: 81
end exclusive: true
exact text: are indicated
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 68

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 219
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism.
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · positive indication candidate

application numbers

NDA021342

brand names

Levothyroxine Sodium

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 659
end exclusive: true
exact text: AGE Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benef
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 20

current approval status

not_reconciled

duplicate text group

dup-470f660ba5ec582682b8

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-a91330c85ba232bd4070

label id

27102784-f56d-4edd-b68b-f8cc89f5b993

positive predicate support span

end: 331
end exclusive: true
exact text: are indicated
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 318

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 459
end exclusive: true
exact text: Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 220

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · limitation of use

application numbers

NDA021342

brand names

Levothyroxine Sodium

classification reasons

limitation_heading

clinical review status

pending

content role

limitation_of_use

context span

end: 679
end exclusive: true
exact text: ng Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatmen
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 260

current approval status

not_reconciled

duplicate text group

dup-492d22213186bdb4d46f

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-78c8b8f8384ece0bf34c

label id

27102784-f56d-4edd-b68b-f8cc89f5b993

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 479
end exclusive: true
exact text: Limitations of Use:
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 460

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 4 · limitation of use

application numbers

NDA021342

brand names

Levothyroxine Sodium

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 979
end exclusive: true
exact text: pression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine sodium tablets is L-thyroxine (T4) indicated for: • H
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 280

current approval status

not_reconciled

duplicate text group

dup-2c414ff1c14935022213

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-b638d7ab0c0756796173

label id

27102784-f56d-4edd-b68b-f8cc89f5b993

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 779
end exclusive: true
exact text: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)].
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 480

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 5 · limitation of use

application numbers

NDA021342

brand names

Levothyroxine Sodium

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1111
end exclusive: true
exact text: xic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine sodium tablets is L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquir
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 580

current approval status

not_reconciled

duplicate text group

dup-937f958e8ac0b6d33680

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-5b8d2328f6cb925046c5

label id

27102784-f56d-4edd-b68b-f8cc89f5b993

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 911
end exclusive: true
exact text: • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 780

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · indication intro context

application numbers

NDA021342

brand names

Levothyroxine Sodium

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 1175
end exclusive: true
exact text: ts may induce hyperthyroidism [see Warnings and Precautions (5.4)]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine sodium tablets is L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1) • Pituitary Thyrotropin (Thyroid-Stimulat
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 712

current approval status

not_reconciled

duplicate text group

dup-3b43c373026b0b5d17d1

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-1731efcb8ab7fdde6bbc

label id

27102784-f56d-4edd-b68b-f8cc89f5b993

positive predicate support span

end: 970
end exclusive: true
exact text: is L-thyroxine (T4) indicated
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 941

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 975
end exclusive: true
exact text: Levothyroxine sodium tablets is L-thyroxine (T4) indicated for:
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 912

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 7 · unclassified context

application numbers

NDA021342

brand names

Levothyroxine Sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1329
end exclusive: true
exact text: )]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine sodium tablets is L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid can
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 776

current approval status

not_reconciled

duplicate text group

dup-ec960f61a2e0c9c173a6

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-1b20af80c1e221593ae1

label id

27102784-f56d-4edd-b68b-f8cc89f5b993

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1129
end exclusive: true
exact text: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism.
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 976

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA021342

brand names

Levothyroxine Sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1333
end exclusive: true
exact text: um tablets is L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 930

current approval status

not_reconciled

duplicate text group

dup-165ce41742a9b7479285

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-000837589aa6e807d76b

label id

27102784-f56d-4edd-b68b-f8cc89f5b993

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1133
end exclusive: true
exact text: (1)
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 1130

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA021342

brand names

Levothyroxine Sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1533
end exclusive: true
exact text: ablets is L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (1) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 934

current approval status

not_reconciled

duplicate text group

dup-5053079f541d60de6f56

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-2703cae83132b2574ec7

label id

27102784-f56d-4edd-b68b-f8cc89f5b993

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1333
end exclusive: true
exact text: • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 1134

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · limitation of use

application numbers

NDA021342

brand names

Levothyroxine Sodium

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1573
end exclusive: true
exact text: • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (1) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 1134

current approval status

not_reconciled

duplicate text group

dup-ce6c1d9152ff20c75767

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-4c79f66ac9179209b4df

label id

27102784-f56d-4edd-b68b-f8cc89f5b993

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1573
end exclusive: true
exact text: (1) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
label id: 27102784-f56d-4edd-b68b-f8cc89f5b993
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 04d90085d89b20ab71c8d4a68db746bf6a9efdcd688f05f959f6a6dee2ce73f4
start: 1334

source url

https://api.fda.gov/drug/label.json?search=id%3A%2227102784-f56d-4edd-b68b-f8cc89f5b993%22

spl effective date

2024-06-03

spl set id

56c633a9-3f64-46bd-b93f-afbff92b5559

spl version

104

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice